ClinicalTrials.Veeva

Menu

The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23

C

Camillians Saint Mary's Hospital Luodong

Status and phase

Unknown
Phase 4

Conditions

Other Nonspecific Abnormal Serum Enzyme Levels

Treatments

Drug: Calcium Carbonate
Drug: Lanthanum carbonate

Study type

Interventional

Funder types

Other

Identifiers

NCT01845090
SMHLANFGF23

Details and patient eligibility

About

To compare the effect of lanthanum carbonate with calcium carbonate on serum FGF23 levels in hemodialysis patients.

Full description

The investigators enrolled patients on maintenance hemodialysis and randomized them to two groups. One group will receive lanthanum carbonate and another group will receive calcium carbonate. The investigators will compare serum FGF23 levels between two groups after they receive above medication for 6 months.

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age > 18 years old
  • Chronic renal failure on maintenance hemodialysis 3 times a week for at least 3 months Serum calcium:8-10.5 mg/dL
  • Serum phosphate:3.5-6 mg/dL(before washout period)
  • Serum phosphate ≧6 mg/dL after washout period
  • Serum i-PTH: 150-600 pg/mL

Exclusion criteria

  • Diabetes mellitus
  • Post parathyroidectomy
  • Life expectancy< 6 months
  • Liver disease(hepatitis B,C or liver dysfunction)
  • Severe gastrointestinal disorders or other severe comorbidity
  • Poor compliance
  • Intolerance to lanthanum or calcium carbonate
  • Active infection
  • Malnutrition(serum albumin<3 g/dL or clinical assessment)
  • Kt/V< 1.2 (inadequate dialysis)
  • Serum phosphate>7.5 mg/dL after washout period

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

30 participants in 2 patient groups

Lanthanum carbonate
Active Comparator group
Description:
Lanthanum carbonate 375mg\~750 mg tid for 6 months
Treatment:
Drug: Lanthanum carbonate
Calcium carbonate
Active Comparator group
Description:
Calcium carbonate 500mg\~1000 mg tid for 6 months
Treatment:
Drug: Calcium Carbonate

Trial contacts and locations

1

Loading...

Central trial contact

Yu-Ming Chang, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems